China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512; CGP) has announced the official commercialization of its subsidiary BlackSwan Vascular, Inc.’s innovative liquid embolic agent, Lava, in the United States. This marks a significant milestone for the company as it expands its presence in the US medical market.
US Market Approval and Product Features
Lava received marketing approval in the US in April of this year, making it the first product of its kind to treat peripheral arterial bleeding. The product’s radiopaque properties make it less prone to artifacts during the imaging process, offering better imaging results. This feature is particularly beneficial for medical professionals, enhancing the precision and effectiveness of treatments.
Potential Synergies and Oncology Applications
Lava is expected to be potentially synergistic with radioisotope brachytherapy and interventional therapy. It is anticipated to be used in combination with CGP’s SIR-Spheres yttrium [90Y] resin microsphere, expanding into oncology indications. This combination could provide new treatment options for patients and healthcare providers, particularly in the field of cancer treatment.
US Unit and Acquisition Details
The US unit, founded in 2017, focuses on developing innovative medical technologies. CGP acquired Lava and Kona, the core products of the US unit, in a USD 37.5 million deal in April 2023, alongside 87.5% stakes. This acquisition underscores CGP’s commitment to expanding its portfolio and enhancing its capabilities in the global healthcare sector.
Conclusion
The commercialization of Lava in the United States represents a strategic step for China Grand Pharmaceutical and Healthcare Holdings Ltd, as it leverages innovative solutions to address critical medical needs. With the potential to revolutionize treatments for peripheral arterial bleeding and expand into oncology, Lava positions CGP as a leader in medical innovation.-Fineline Info & Tech
